pendent (TD) patients [HR 0.41; 95% credible interval (CrI) 0.29-0.56], and this effect did not appear to interact significantly with illness severity (interaction coefficient HR 1.38; 95% CrI 0.62-3.41). A meta-analysis of studies where patients acquired TI was not possible, but those studies consistently reported a survival benefit for those who acquired TI. Conclusion: The findings revealed a 59% pooled reduction in mortality among TI patients when compared with TD patients.
Prognostic Scoring System which replaced the International Prognostic Scoring System (IPSS) cytopenia category with transfusion dependence (TD). The depth of anemia correlates with TD and poor outcomes in MDS [2] . The precise reasons for the impact of transfusion status remain unclear, although it may be an indicator of underlying disease severity [3] and transfusions may lead to iron overload, which can cause organ dysfunction and death [4, 5] .
Although the prognostic significance of TD is widely acknowledged, no systematic review has assessed the impact of transfusion status on overall survival (OS) in patients with MDS. It is also unclear whether the association varies according to illness severity (although isolated studies have provided some analysis of this) [6] [7] [8] [9] and whether it holds for patients who achieve transfusion independence (TI) through treatment.
This study aimed to conduct a systematic review and meta-analysis of the association between OS and TI in patients with MDS. It further aimed to assess whether the association is modified by patient risk category and to assess the association in those who acquired TI through treatment.
Methods
The systematic review followed the principles recommended in the PRISMA statement [10] . The protocol is published in the PROSPERO database (http://www.crd.york.ac.uk/PROSPERO; record CRD42014007264).
Searches
Comprehensive electronic searches were conducted in 5 key bibliographic databases (MEDLINE, EMBASE, Cochrane Library, CINAHL and Science Citation Index), from inception to January 3, 2014, and updated in MEDLINE only on May 7, 2014 . Sensitive key word strategies using free text and thesaurus terms were developed. Boolean operators and database-specific syntax were used to combine synonyms related to MDS and TD. Terms related to survival outcomes were not used because a scoping search found these were too restrictive due to a lack of survival outcome reporting in abstracts. Searches were limited to human studies only. An example of the search strategy used (from MEDLINE) is available as an online supplementary appendix (for all online suppl. material, see www. karger.com/doi/10.1159/000445163). Relevant conference proceedings were searched electronically, experts were contacted for additional studies, grey literature (guidelines and unpublished and unindexed studies) was searched online and the reference lists of relevant reviews and guidelines were checked to ensure data saturation.
Study Selection
Studies were included if they had recruited adults aged >18 years with a confirmed diagnosis of MDS and had reported OS for TI patients versus TD patients. Studies recruiting >20% pediatric or primary AML patients were excluded. Studies were not excluded on the basis of changes in MDS definitions. Studies with any proportion of patients with AML secondary to MDS were included. Studies recruiting any patients with conditions other than these were excluded. Transfusion status expressed (or calculable) as units transfused per unit time was acceptable; however, total units transfused was not acceptable because this is not an indicator of degree of dependence. Studies comparing patients who acquired TI (e.g. through treatment) with those who did not were included but analyzed separately. Any expression of OS was acceptable, although only hazard ratios (HRs) were included in the meta-analysis. Studies only reporting predicted survival, progression-free survival or composite outcomes such as 'survival or progression to AML' were excluded. Studies with a follow-up of <6 months were excluded because short follow-ups may miss the effects of transfusion status. Studies with unclear follow-up length were included to avoid excluding potentially relevant studies on the basis of poor reporting. Randomized controlled trials (RCTs), cohort studies, consecutive case series of ≥ 10 cases, before-after studies and casecontrol studies were included. Non-English-language studies were included if an English-language abstract described the study type, population and outcome in sufficient detail.
Data Extraction
A standardized data extraction form was developed following the recommendations in the Centre for Reviews and Dissemination Handbook [11] and piloted on studies of different designs. Data were extracted by one reviewer and checked by another. Disagreements were resolved through discussion or the involvement of a third reviewer.
Quality Assessment
Study quality was assessed using the validated Quality in Prognosis Studies (QUIPS) tool [12] adapted for this review. All items were included and scored as low risk, high risk or unclear risk (moderate and unclear risk as defined in the QUIPS guidelines). These included the assessment of: representativeness of study sample (selection bias), difference in key patient characteristics between those excluded or lost and those included (attrition bias), differences in TD measurement in those who survived versus those who did not (prognostic factor measurement bias), differences in OS measurement in TD versus TI patients (detection bias), how potential confounders were dealt with (confounding) and appropriateness of the statistical analysis (statistical analysis and reporting bias). Potential confounders of highest priority were IPSS or cytogenetics, WHO stage and age. Studies were scored for confounding according to whether some (unclear risk), all (low risk) or none (high risk) of these characteristics were accounted for in the analysis. For the statistical analysis item, studies were scored as 'unclear' when the Kaplan-Meier curves or multiple Cox regression analyses were not conducted or as 'high risk' when neither was conducted.
Narrative Synthesis
A narrative synthesis, including the tabulation of results and a consideration of clinically meaningful patterns, was conducted. Data were grouped by risk category of included patients and study type. Cohorts were classed as 'high risk' if inclusion was restricted to IPSS int-2 [13] , patients with high-risk disease or those in WHO MDS subgroups [14] with excess blasts. Conversely, low-risk co-
Meta-Analysis
Meta-analyses were conducted for studies that presented HRs. A Bayesian Markov chain Monte Carlo approach was conducted in WinBUGS, with a random-effects model to allow heterogeneity in the effect of TI on OS across studies. When HRs were expressed for TD rather than TI, the ratio was converted by dividing 1 by the reported HR.
Multiple Cox regression analyses were selected when presented because these corrected for confounding variables. To avoid double counting, only nonoverlapping cohort studies were included. When studies overlapped each other, 1 study was selected for inclusion in the meta-analysis by excluding studies with the narrowest patient spectrum (e.g. studies that only recruited patients who had an allogeneic stem cell transplant), studies with less adequate covariate adjustments in the multiple Cox regression analysis (see the definition in the Quality Assessment section), studies in which another study included additional patients (e.g. 2 extra years of data or abstracts when a full journal article was available) and studies lacking the recruitment date or location information which prevented an assessment of overlap. For studies with an unreported standard error, 95% confidence interval (CI) or exact p value (e.g. only reported p < 0.001), the p value was treated as the exact p value in the analysis (e.g. p = 0.001 when p < 0.001 was reported).
Sensitivity analyses were conducted which included univariate Cox regression analyses when multiple Cox regression analyses were not presented and included studies that only reported Kaplan-Meier curves. For the latter, Kaplan-Meier curves were digitized and patient-level data were reconstructed using the approach published in Guyot et al. [15] to obtain the estimated HR. A metaregression was conducted to investigate whether the effect of TI on OS differed according to patient risk category.
Results
The total number of unique records considered for inclusion was 1,842 ( fig. 1 ). Of these, 1,641 were identified through electronic searching, 80 of which were included in the review. Expert sources and chance find articles contributed 4 additional articles. The reference lists of 45 reviews were checked for titles not retrieved by electronic searches, and 186 additional unique titles were considered for inclusion. Of these, 5 met the inclusion criteria and were selected for the review. No further unique titles were identified from the final reviews checked, thus achieving data saturation. In total, 89 articles were included in the review, representing 55 separate but often overlapping data sets. All studies and their parallel publications (in which no unique patients were analyzed) are listed in table 1 .
Risk of Bias
Measurement of TD and OS was consistent in most studies, and statistical analyses were appropriate in most cases (i.e. log-rank test in univariate analyses, with multiple Cox regression models for >1 covariate; fig. 2 ). There was a low risk of attrition bias in approximately 50% of the studies, with unclear reporting of attrition being a common issue. Many studies exhibited issues with cohort representativeness (e.g. studies only including participants with available bone marrow biopsies) and covariate adjustment. A diagrammatic representation of the risk of bias assessment for each study is included in the online appendix (online suppl. fig. 1 ).
Narrative Synthesis
Three main study types were identified: (A) studies that recruited both TD and TI patients at baseline and compared OS between these 2 groups (generally retrospective cohort studies), (B) studies that recruited only TD patients and compared the OS of those who became TI after treatment with those who remained TD (generally RCTs) and (C) studies that recruited only TD patients at baseline and compared the OS of those with a high transfusion burden with those with a low transfusion burden (generally retrospective cohort studies; the same cutoff point was sometimes used to categorize patients as low burden in these studies as was used to categorize TI in the type A studies, but patients with no transfusions were missing). Most data sets (n = 43, reported across 70 publications) were type A, 4 were type B (reported across 9 publications) and 5 were type C ( table 1 ). Three studies were not study type A, B or C: Rojas et al. [16] recruited all TI patients at baseline and compared OS in those who became TD with those who did not and both Jädersten et al. [17] and List et al. [18] analyzed transfusion status as a continuous variable.
The studies were conducted in different countries and settings, most commonly in the USA, followed by Italy and Germany. Several included patients from >1 country or center. Most (n = 36) did not select patients on the basis of risk (unselected cohorts), although 16 were conducted with patients with low-risk disease only and 3 with high-risk disease only. Two unselected cohorts [6, 19] reported a low-risk subgroup analysis, and 1 study [9] reported both high-and low-risk subgroup analyses in separate publications [7, 8] . The risk group was unclear in 1 study and was categorized as unselected [20] . Study cohort size ranged from 37 [21] to 9,820 [22] . However, the total number of patients included in the review is unclear because multiple studies drew patients from the same Excluded at title Reference lists of reviews: n = 0 Chance finds: n = 0
Excluded at abstracet Reference lists of reviews: n = 43 Chance finds: n = 1
Excluded at full text Reference lists of reviews: n = 132 Chance finds: n = 0
Reviews (screened for references) n = 3
Reasons for exclusion: >20% primary AML: n = 1 Case series n < 10: n = 1 Letter: n = 1 No data on TI:OS: n = 122 Not English language: n = 1 Platelet transfusion: n = 2 Total load not burden: n = 1 Review: n = 3
Excluded at title n = 252
Excluded at full text n = 404
Excluded at abstract n = 899
Reviews (screened for references) n = 93 locations over overlapping time periods, and cohorts or parts of cohorts were often included in several studies ( table 1 ).
Results from each study are presented in tables 2-5 . To minimize the impact of double-counting participants on the narrative synthesis, studies that drew data from patient cohorts that were entirely independent from each other are listed first. Studies that drew data from overlapping (or potentially overlapping) patient cohorts are grouped together, and studies for which this could not be ascertained are also grouped together.
As seen in tables 2-5 , TI was consistently associated with an OS benefit for patients with MDS, and the effect was usually statistically significant, with only a few exceptions.
For study type A ( [6] . Studies that recruited only patients with high-risk disease had a lower range of HRs in the multiple Cox regression analyses (1.04; 95% CI n.r.; p = 0.85 and 1.9; 95% CI 1.4-2.6; p ≤ 0.0001) [7, 23] [6, 24] . In 2 of the 3 highrisk studies, the HR was nonsignificant [7, 25] . Of the 34 studies, only 7 did not report a statistically significant HR [7, [26] [27] [28] [29] [30] [31] .
Other analyses reported in the type A studies included mean and median survival times, mortality rates at a point in time and univariate Cox regression analyses. In all cases, a numerically favorable survival was reported for TI. Of 37 studies in which statistical significance was reported, only 5 reported a nonsignificant difference [26, [28] [29] [30] 32] .
All but 2 type B studies drew patient data from one or both of the lenalidomide trials, MDS-003 and MDS-004, and recruited del(5q) patients with low-risk disease. The HRs from the multiple Cox regression analyses, expressed as TI versus TD (values <1 indicated better survival for TI patients) ranged from 0.3584 (95% CI n.r.; p < 0.001) [33] to 0.53 (95% CI 0.31-0.91; p = 0.021) [34] and were statistically significant, apart from 1 that drew a small sample of patients with bone marrow samples available (n = 39) from the MDS-003 trial [35] . and TI at baseline 61% became TD during treatment ASCT = Autologous stem cell transplant; ATG = antithymocyte globulin; AZA = azacitidine; CMML = chronic myelomonocytic leukemia; EUMDS = European LeukemiaNet MDS registry; GCSF = granulocyte colony-stimulating factor; HSCT = hematopoietic stem cell transplant; I = independent cohort; O = overlapping cohort; RAEB-T = refractory anemia with excess blasts in transition; RS = ringed sideroblasts; U = extent to which cohort is independent or overlapping is unknown. high-risk disease and treated them with azacitidine [36] and the other was a reanalysis of two decitabine trials [62] . Both studies reported that achieving TI was associated with a lower risk of death (table 3 ). All the type C studies, whether on low-risk or all-risk patients, reported that low-burden TD was associated with better OS compared with high-burden TD ( table 4 ) . HRs were sometimes unexpectedly high (78.1; 95% CI n.r.; p < 0.05) [21] , although this particular analysis had only 14 patients. Large differences in the HRs reported for patients with low-risk disease (range 1.056-78.1) prevented drawing any meaningful observations about whether the association between low-burden TD and OS was different in the low-or all-risk studies. The reanalysis of MDS-003/004 data [37] showed only a small HR between low-burden and high-burden TD patients.
Meta-Analysis
Analysis 1: Meta-Analysis of All Eligible Studies (Study Type A) Ten studies [6, 9, 19, 24, [38] [39] [40] [41] [42] [43] were included in the meta-analysis of type A studies (regardless of risk category) reporting the multiple Cox regression analysis HR for the OS of TI patients compared with TD patients. Analyzed cohort size ranged from 63 [6] to 840 [40] . Only low-and all-risk subgroups were included in the analysis because none of the 3 studies that recruited patients with high-risk disease were eligible for inclusion due to: (1) an overlap of the patient cohort with other studies [23] , (2) the multiple Cox regression analysis in Komrokji et al. [7] had already corrected for transfusion status and (3) data were not reported for the univariate or multiple Cox regression analyses ( table 4 ) [25] . Two of 10 studies [24, 39] selected only patients with low-risk disease whereas the rest selected patients with any severity or risk disease. The meta-analysis showed that TI was associated with a 59% decrease in the risk of death compared with TD [HR 0.41; 95% credible interval (CrI) 0.29-0.56; fig. 3 ]. The estimated between-study SD was 0.39 (95% CrI 0.18-0.83), implying moderate heterogeneity between studies in the effects of TI.
A sensitivity analysis was conducted to check the robustness of the estimates by including studies that had reported univariate Cox regression analyses but not a multiple Cox regression analysis [44] and those that had only published Kaplan-Meier curves [26, [45] [46] [47] . In it, TI was associated with a 59% decrease in the risk of death compared with TD (HR 0.41; 95% CrI 0.32-0.51; fig. 4 ). The estimated between-study SD was 0.32 (95% CrI 0.16-0.59).
Analysis 2: Meta-Regression for Different Patient Risk Categories (Study Type A)
A random-effects, meta-regression analysis was conducted to assess whether the effect of TI on OS depended on the risk group of the patients included. The same 10 studies used in analysis 1 were included.
The estimated coefficient of the interaction term was an HR of 1.38 (95% CrI 0.62-3.41), which indicated the possibility of no interaction. Hence, the meta-regression [7] , 2011
1.04 (n.r.; p = 0.85) univariate analysis (HR) significant (p = n.r.) AZA = Azacitidine; FAB = French American British; n.s. = not significant; RAEB = refractory anemia with excess blasts; RBC = red blood cell. a 95% CI; p value; TD vs. TI unless otherwise stated. b As was reported in the source document. b TI versus TD. suggested that the magnitude of the benefit on OS from TI was higher for all risk groups, but this was inconclusive.
The analysis also showed that TI was associated with a 62% decrease in the risk of death compared with TD for the all-risk groups (HR 0.38; 95% CrI 0.25-0.55) and with a 47% decrease in the risk of death compared with TD for the low-risk groups (HR 0.53; 95% CrI 0.25-1.12). The estimated between-study SD was 0.41 (95% CrI 0.19-0.92), which implied moderate heterogeneity between studies in the effects of TI.
The sensitivity analysis, including studies that did not use multiple Cox regression, showed that TI may have had more benefit on OS among the all-risk groups, but, again, the effect was inconclusive (HR of low-risk group vs. all-risk group 1.45; 95% CrI 0.87-2.50). It also showed that TI was associated with a 62% decrease in the risk of death compared with TD in the all-risk groups (HR 0.38; A meta-analysis was also planned to assess the impact on OS of becoming TI for patients who were TD at baseline, potentially including 3 studies [33, 34, 48] . However, there was too much overlap in the study cohorts to permit a meta-analysis.
Discussion
This systematic review is the first to investigate the benefits of being TI (study type A) or becoming TI (study type B) on the OS of patients with MDS. The narrative synthesis of findings revealed a consistent reduction in mortality among TI patients compared with TD patients, in both those who were TI at recruitment and those who achieved TI through treatment. In this meta-analysis, the reduction in mortality was estimated to be 59% for those who were TI at recruitment compared to those who were TD at recruitment, when all risk categories were included (analysis 1). No meta-analysis was possible for studies in which patients achieved TI through treatment (analysis 3), but the 59% estimate for those who were TI at recruitment falls within the range of reductions for those who achieved TI through treatment, i.e. 47-64% (HR range 0.53-0.36).
The meta-regression of different risk categories was limited by the small number of studies reporting HRs in the high-risk (n = 0), low-risk (n = 2) and all-risk (n = 9) categories for study type A. The test for an interaction between a risk group and the effect of TI on OS suggested the possibility of no interaction by risk group because the CrI for the interaction was inconclusive. Narrative results for the high-risk studies suggested a much lower range of HRs compared with the all-risk and low-risk studies, but the range of CI of the low-risk and high-risk groups overlapped ( table 2 ) . Hence, it is currently impossible to determine whether there is a differential effect of TI on OS, depending on the risk category of the patients. Compounding this, 1 limitation for both analyses 1 and 2 is that the all-risk group studies were treated the same, regardless of the proportions of risk categories within each study because not all studies reported these data. Studies that recruited all TD patients at baseline and compared those with a higher transfusion burden and those with a lower burden (type C studies) had a very wide range of HRs, preventing any meaningful conclusions from being drawn. Among these were 2 reanalyses of MDS-003/004 data, which reported the smallest HRs in this analysis set. This may be a product of lenalidomide treatment, which may have altered the relative risk of death between the high-and low-burden patients compared with untreated patients.
A small number of studies (n = 8) [7, 25-29, 31, 35] reported that the survival difference between TD and TI patients did not reach statistical significance in the multiple Cox regression analyses. These studies had some unusual characteristics. Komrokji et al. [7] and Cermak et al. [25] were both conducted on patients with high-risk disease, for whom the expected OS may have been too short to show any significant benefit. Platzbecker et al. [28] and Cermak et al. [25] selected patients who had undergone allogeneic stem cell transplant, and the former suggested that this intervention may be protective against the prognostic disadvantage of transfusion requirement. Buesche et al. [35] selected a small subsample of del(5q) patients with available bone marrow samples from the MDS-003 trial, which may have resulted in underpowering or a spectrum bias, both of which could have contributed to the nonsignificant result. Wallvik et al. [26] treated anemic patients (TD and TI) with epoetin and corrected for epoetin response. However, a greater proportion of TI patients responded (54%) than TD patients (21%); therefore, correcting for response is, in part, correcting for transfusion status. The study by Rojas et al. [16] was unique because it recruited all TI patients at baseline and followed them through disease progression, whether they were treated or untreated. The comparison was median survival, which at the last follow-up had not been reached in the TI group, and so the analysis may not reflect the true survival difference between groups. Finally, the patients in Lim et al. [29] were treated with antithymocyte globulin, an intervention that aims to promote hematologic response. Indeed, it appears that the analysis in this study was for baseline TI, which may have been confounded by the approximate 30% of TD patients who became TI during treatment. The impact of these treatments and patient characteristics on the relationship between TI and OS, however, remains underresearched and is worth exploring in future trials and cohort studies. One further study reported nonsignificant results in 1 analysis [32] in which only those with <5% blasts and ≥ 1% ring sideroblasts were selected, but a significant HR in the 2 other analyses, in which (1) all patients were selected [31] and (2) only those with >15% ring sideroblasts were selected [49] .
This systematic review has been conducted to high standards following an a priori protocol published in the PROSPERO database. It included comprehensive search techniques that reached data saturation, validation of the study selection and data extraction, a quality assessment of the included studies, an inclusive narrative synthesis and a bespoke meta-analysis. It represents the first formal meta-analysis of this association by systematic review, and care was taken to avoid double-counting within a very challenging data set.
Study Limitations and Future Research
The definition of TI varied across the literature and was frequently unreported. This may have affected the meta-analysis results, and the potential impact of TI definition on HRs is worthy of further investigation. Due to a lack of suitable data, no meta-analysis was performed for high-risk cohorts and the meta-analysis for low-risk disease included only 2 studies, meaning that the effect of TI within this group was associated with considerable uncertainty. The exclusion of non-English-language studies may have resulted in relevant data being missed. Additionally, the search strategies and study selection process relied on terms included in the abstract. This potential problem was mitigated through the checking of references from a large number of relevant reviews (n = 45) to data saturation, which yielded 6 additional included studies. It is therefore likely that most relevant studies were included.
In conclusion, previous studies have suggested that patients with MDS who are TI have better survival relative to those who are TD, but no meta-analysis had been conducted to date. Our findings revealed a consistent, substantial reduction in mortality among TI patients compared with TD patients, confirming the positive TI-OS association. A meta-regression indicated that the impact of TI was higher in the all-risk cohorts versus the low-risk cohorts, but this effect was inconclusive. A similar association was seen for those who acquired TI through treatment.
